Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
12.01. | FDA grants two designations for GenFleet's drug candidate SLS009 | ||
11.01. | Fermion receives IND approval in China for pain relief drug FZ008-145 | ||
10.01. | AbbVie introduces Produodopa for advanced Parkinson's in EU | ||
09.01. | Simcha Therapeutics signs license agreement with Janssen for DR-18 | ||
08.01. | AOB Pharma, Maruho partner to develop B244 for inflammatory ailments | ||
05.01. | AGC Biologics to build new facility in Japan | ||
04.01. | Kyverna Therapeutics' IND application for MS therapy receives FDA clearance | ||
03.01. | WuXi XDC, IntoCell partner for drug-linker technology and CRDMO services | ||
02.01. | Alfasigma to acquire Galapagos' Jyseleca business | ||
29.12.23 | Palisade Bio receives milestone payment for PALI-2108 development | ||
28.12.23 | Eli Lilly concludes POINT Biopharma acquisition for $1.4bn | ||
27.12.23 | Innovent and SanegeneBio partner for hypertension drug development | ||
26.12.23 | FDA grants priority review for Daiichi Sankyo-Merck's lung cancer therapy | ||
22.12.23 | SELLAS receives orphan drug designation for PTCL therapy | ||
21.12.23 | Calliditas receives approval for Nefecon to treat IgAN | ||
20.12.23 | LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate | ||
19.12.23 | Allay grants acute pain management drug license to Japan's Maruishi Pharmaceutical | ||
18.12.23 | Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis | ||
15.12.23 | Merck gets FDA approval for WELIREG to treat advanced renal cell carcinoma | ||
14.12.23 | Aldevron signs agreement to acquire license to Codex HiCap RNA Polymerase | ||
13.12.23 | Almirall signs alliance with etherna for new mRNA-based therapies | ||
12.12.23 | Lavipharm signs agreement with Sanofi to acquire Flagyl | ||
11.12.23 | Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML | ||
08.12.23 | USFDA accepts NextPoint Therapeutics's IND for NPX887 | ||
07.12.23 | Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme |